Start-Up Quarterly Statistics, Q3 2013
This article was originally published in Start Up
Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.
You may also be interested in...
Two Days, Two Deals: AbbVie To Partner (Again) With Galapagos In Cystic Fibrosis
AbbVie’s busy week continued when it unveiled a collaboration with Galapagos in cystic fibrosis Sept. 24, a day after it announced an inflammatory disease tie-up with Ablynx. AbbVie and Galapagos already are partnered under a 2012 deal in rheumatoid arthritis and Crohn’s disease.
Nanobody Specialist Ablynx Bags Global IL-6R Deal With AbbVie
Ablynx stands to get $840 million and double-digit royalties under a global license deal with AbbVie to develop and commercialize the Belgian group’s anti-IL-6R candidate ALX-0061 to treat inflammatory diseases. The transaction brings a big boost to the biotech’s prospects.
VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.